The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Atrial fibrillation was diagnosed in 477 of 1,501 (31.8%) participants in the monitoring group and 550 of 4,503 (12.2%) participants in the control group (HR 3.17, 95% CI 2.81-3.59, P<0.001), reported ...

Many insertable cardiac monitors, known as ICMs or loop recorders, are already able to stay in place under the skin for several years at a time, enabling long-term tracking of irregular heartbeats—but ...